Zenas BioPharma, Inc. (ZBIO) Profit Margins
Over the twelve months to 2026-06-30, Zenas BioPharma, Inc. (ZBIO) had operating margin -47557.3%, net margin -48438.4%, free cash flow margin -22597.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZBIOZenas BioPharma, Inc.Follow ZBIO — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating margin | -3277.8% | -3830.6% | -47557.3% | |
| Net margin | -3139.8% | -3777.4% | -48438.4% | |
| FCF margin | -2396.1% | -1723.5% | -22597.4% |
USD millions · SEC XBRL
Zenas BioPharma, Inc. — questions
- What is Zenas BioPharma, Inc.'s operating margin?
- -47557.3% over the twelve months to 2026-06-30.
- What is Zenas BioPharma, Inc.'s net profit margin?
- -48438.4% over the twelve months to 2026-06-30.
Every figure on this page comes from Zenas BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.